Mar 2026 (Q3 FY26) — May 6, 2026
Bio-Techne Q3 FY26 — Mixed Market, Strong Pharma, Spatial Biology Growth
Read the full callBio-Techne (TECH) earnings
- Jun 2026
- Mar 2026 (Q3 FY26)
- Jun 2026
Bio-Techne earnings: last reported Wed, 6 May 2026, for the quarter ended Mar 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 321 | +1.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 23.1 | +30.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. |
Guidance
What management said, and what became of it
11 of 13 judged targets kept · 7 open · verdicts reflect calls analysed to Mar 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Cell therapy FDA Fast Track order-timing headwind to organic growth | approximately 300 basis points | Dec 2025 | The timing impact from our 2 largest cell therapy customers who received FDA Fast Track designation was a 3% headwind, while a large OEM commercial supply order that we typically receive in Q3 but received in Q2 of this year was an additional 1% headwind to revenue. | Achieved |
| Q3 FY26 underlying organic revenue growth excluding cell therapy and OEM timing items | mid-single digits | Dec 2025 | Adjusting for these previously disclosed items, organic growth was plus 2% for the quarter. | Missed |
| FY26 adjusted operating margin expansion | approximately 100 basis points, starting flat YoY in Q1 and ramping to ~200bps higher by Q4 | Jun 2025 | Adjusted operating margin was 34.2%, down 70 basis points year-over-year. | Revised Down |
2 of BIO-TECHNE Corp's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.
Claimed
- Spatial Biology portfolio delivered mid-teens growth, with COMET platform growing over 65% and achieving a record backlog.
- GMP protein portfolio grew nearly 50% year-over-year when excluding two fast track cell therapy customers.
- Large pharma customers delivered low double-digit growth for the sixth consecutive quarter.
- China end market achieved positive organic growth for the fourth consecutive quarter (low single digits).
- Adjusted operating margin improved sequentially to 34.2%, representing a 310 basis point improvement over fiscal Q2.
Qualified
- Overall organic revenue declined 2% for the quarter.
- Emerging biotech revenues declined high single digits, offsetting large pharma strength.
- Protein Sciences organic revenue declined 4% (or 2% underlying excluding timing impacts).
- Bio-Techne Diagnostics declined low single digits due to order timing from certain large customers.
- Q4 FY26 organic growth is expected to be approximately flat.
Price
$72.49 −0.11% · −$0.08
Performance +94.6% 1Y
1Y: $37.25 on 17 Oct 2025 → $72.49. High $72.61 (25 Sept 2026), low $28.23 (1 Jul 2026).
- Previous close
- $72.57
- 52-week range
- $28.23 – $72.61
- One year
- +92.64%
Overview
- Symbol
- TECH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
11 of 13 judged targets kept · 7 open · verdicts reflect calls analysed to Mar 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Cell therapy FDA Fast Track order-timing headwind to organic growth | approximately 300 basis points | Dec 2025 | The timing impact from our 2 largest cell therapy customers who received FDA Fast Track designation was a 3% headwind, while a large OEM commercial supply order that we typically receive in Q3 but received in Q2 of this year was an additional 1% headwind to revenue. | Achieved |
| Q3 FY26 underlying organic revenue growth excluding cell therapy and OEM timing items | mid-single digits | Dec 2025 | Adjusting for these previously disclosed items, organic growth was plus 2% for the quarter. | Missed |
| FY26 adjusted operating margin expansion | approximately 100 basis points, starting flat YoY in Q1 and ramping to ~200bps higher by Q4 | Jun 2025 | Adjusted operating margin was 34.2%, down 70 basis points year-over-year. | Revised Down |
Claimed
- Spatial Biology portfolio delivered mid-teens growth, with COMET platform growing over 65% and achieving a record backlog.
- GMP protein portfolio grew nearly 50% year-over-year when excluding two fast track cell therapy customers.
- Large pharma customers delivered low double-digit growth for the sixth consecutive quarter.
- China end market achieved positive organic growth for the fourth consecutive quarter (low single digits).
- Adjusted operating margin improved sequentially to 34.2%, representing a 310 basis point improvement over fiscal Q2.
Qualified
- Overall organic revenue declined 2% for the quarter.
- Emerging biotech revenues declined high single digits, offsetting large pharma strength.
- Protein Sciences organic revenue declined 4% (or 2% underlying excluding timing impacts).
- Bio-Techne Diagnostics declined low single digits due to order timing from certain large customers.
- Q4 FY26 organic growth is expected to be approximately flat.
The full ledger
Open BIO-TECHNE Corp’s full ledger
A free account opens 5 company ledgers a month. All 20 tracked commitments, with each call’s wording and source.
Call summaries
Every analysed call
Bio-Techne earnings calls (TECH)
Financials
What the filings say
Net profit, year on year: +126% (quarter to mar 2026 against mar 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 289 | 297 | 316 | 317 | 287 | 296 | 311 | 321 |
| Operating profit | 40 | 47 | 39 | -24 | 48 | 54 | 75 | 74 |
| Operating margin | 13.8% | 16.0% | 12.2% | −7.5% | 16.6% | 18.4% | 24.2% | 23.1% |
| Other income | 0 | -5 | -0 | 1 | 0 | -4 | -4 | -4 |
| Interest | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 |
| Profit before tax | 40 | 43 | 38 | -23 | 48 | 51 | 71 | 71 |
| Tax rate | 16.4% | 18.6% | 41.0% | 22.7% | 20.4% | 25.2% | 28.3% | 22.7% |
| Net profit | 34 | 35 | 23 | -18 | 38 | 38 | 51 | — |
| EPS ($ per share) | 0.21 | 0.22 | 0.14 | — | 0.25 | 0.24 | 0.33 | — |
| Line item | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 932 | 1,057 | 1,085 | 1,123 | 1,309 | 1,325 | 1,066 | 1,144 |
| Total liabilities | 719 | 646 | 692 | 594 | 672 | 635 | 639 | 479 |
| Fixed assets | 154 | 177 | 208 | 223 | 226 | 251 | 246 | 232 |
| Investments | — | — | — | 74 | 24 | 1 | — | — |
| Total assets | 1,884 | 2,028 | 2,263 | 2,295 | 2,639 | 2,704 | 2,558 | 2,587 |
| Line item | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 182 | 205 | 352 | 325 | 254 | 299 | 288 | 292 |
| Cash from investing | -337 | 27 | -244 | -97 | -266 | -203 | -35 | -18 |
| Cash from financing | 134 | -184 | -63 | -243 | 23 | -122 | -254 | -169 |
| Net cash flow | -21 | 46 | 52 | -27 | 8 | -29 | 10 | 103 |
| Capital expenditure | -25 | -52 | -44 | -45 | -38 | -63 | -31 | -29 |
| Free cash flow | 156 | 153 | 308 | 280 | 216 | 236 | 257 | 263 |
TECH revenue by segment
Protein Sciences grew from 71% to 72% of revenue over the last two years.
| Segment | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | 71% | 71% | 72% | 71% | 71% | 73% | 73% | 72% | +2.1% |
| Diagnostics and Spatial Biology | 29% | 28% | 28% | 28% | 28% | 27% | 27% | 28% | +0.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q4 FY2026 · share of revenue
- US 52% ↓ 5 pt
- EMEA Excluding UK 25% ↑ 5 pt
- CN 8%
- APAC Excluding Greater China 7% ↑ 1 pt
- GB 5%
- Rest Of World 4%
As TECH cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
61 filings between Oct 30, 2025 and Sep 28, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$437.2K
2 sales by 1 insider
Compensation
not trading decisions- 8
- Award — granted as compensation
- 26
- Option exercise — converted options into shares
- 25
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Herr Amy E. | — | $437.2K | May 8, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2026 | HIGGINS JOHN L Director | Tax withheld | 5,562 | $403.3K |
| Sep 28, 2026 | HIGGINS JOHN L Director | Option exercise | 15,940 | $0 |
| Sep 22, 2026 | BAUMGARTNER ROBERT V Director | Tax withheld | 5,559 | $403.3K |
| Sep 22, 2026 | BAUMGARTNER ROBERT V Director | Option exercise | 15,940 | $0 |
| Aug 15, 2026 | Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 5,423 | $0 |
| Aug 15, 2026 | Geist William PRESIDENT, PROTEIN SCIENCES | Option exercise | 6,416 | $0 |
| Aug 15, 2026 | Kelderman Kim Chief Executive Officer | Tax withheld | 10,821 | $783.4K |
| Aug 15, 2026 | Bohnen Shane SVP - General Counsel | Option exercise | 4,350 | $0 |
| Aug 15, 2026 | Hippel James CFO | Tax withheld | 4,310 | $312.0K |
| Aug 15, 2026 | Kelderman Kim Chief Executive Officer | Option exercise | 21,470 | $0 |
| Aug 15, 2026 | Hippel James CFO | Option exercise | 9,779 | $0 |
| Aug 15, 2026 | Bohnen Shane SVP - General Counsel | Tax withheld | 1,343 | $97.2K |
| Aug 15, 2026 | Crouse Steven C. President - Diag & Spatial Bi | Tax withheld | 1,947 | $141.0K |
| Aug 15, 2026 | Herr Amy E. Director | Option exercise | 589 | $0 |
| Aug 15, 2026 | Herr Amy E. Director | Tax withheld | 213 | $15.4K |
| Aug 15, 2026 | Geist William PRESIDENT, PROTEIN SCIENCES | Tax withheld | 1,976 | $143.1K |
| Jul 29, 2026 | Hippel James CFO | Tax withheld | 51,024 | $3.68M |
| Jul 29, 2026 | Hippel James CFO | Option exercise | 62,068 | $2.95M |
| Jul 28, 2026 | Kelderman Kim Chief Executive Officer | Tax withheld | 28,686 | $2.07M |
| Jul 28, 2026 | Kelderman Kim Chief Executive Officer | Option exercise | 35,000 | $1.67M |
| Jul 23, 2026 | Bohnen Shane SVP - General Counsel | Option exercise | 448 | $21.3K |
| Jul 23, 2026 | Bohnen Shane SVP - General Counsel | Tax withheld | 344 | $24.7K |
| Jun 2, 2026 | Crouse Steven C. President - Diag & Spatial Bi | Tax withheld | 216 | $10.8K |
| Jun 2, 2026 | Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 600 | — |
| May 8, 2026 | Herr Amy E. Director | Sale | 6,636 | $320.4K |
| May 8, 2026 | Herr Amy E. Director | Option exercise | 6,636 | $315.9K |
| May 5, 2026 | Kelderman Kim Chief Executive Officer | Option exercise | 26,692 | $1.27M |
| May 5, 2026 | Hippel James CFO | Tax withheld | 56,955 | $3.23M |
| May 5, 2026 | Hippel James CFO | Option exercise | 62,000 | $2.95M |
| May 5, 2026 | Kelderman Kim Chief Executive Officer | Tax withheld | 23,951 | $1.36M |
| May 5, 2026 | Bohnen Shane SVP - General Counsel | Tax withheld | 7,055 | $399.9K |
| May 5, 2026 | Bohnen Shane SVP - General Counsel | Option exercise | 8,400 | $399.8K |
| May 1, 2026 | Crouse Steven C. President - Diag & Spatial Bi | Tax withheld | 311 | $17.1K |
| May 1, 2026 | Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 794 | — |
| Apr 22, 2026 | Hippel James CFO | Option exercise | 62,000 | $0 |
| Apr 22, 2026 | Hippel James CFO | Tax withheld | 56,097 | $3.29M |
| Apr 22, 2026 | Kelderman Kim Chief Executive Officer | Tax withheld | 1,363 | $79.8K |
| Apr 22, 2026 | Kelderman Kim Chief Executive Officer | Option exercise | 11,344 | $0 |
| Apr 14, 2026 | Kelderman Kim Chief Executive Officer | Tax withheld | 32,088 | $1.88M |
| Apr 14, 2026 | Kelderman Kim Chief Executive Officer | Option exercise | 36,500 | $0 |
| Apr 3, 2026 | Bohnen Shane SVP - General Counsel | Option exercise | 2,259 | $0 |
| Apr 3, 2026 | Bohnen Shane SVP - General Counsel | Tax withheld | 740 | $39.3K |
| Feb 17, 2026 | Herr Amy E. Director | Sale | 1,976 | $116.8K |
| Feb 3, 2026 | Herr Amy E. Director | Option exercise | 38 | $0 |
| Feb 3, 2026 | Herr Amy E. Director | Tax withheld | 16 | $1.0K |
| Feb 1, 2026 | McManus Matthew President - Diag & Spatial Bio | Tax withheld | 1,665 | $106.7K |
| Feb 1, 2026 | McManus Matthew President - Diag & Spatial Bio | Option exercise | 4,621 | $0 |
| Nov 3, 2025 | Kelderman Kim Chief Executive Officer | Tax withheld | 2,303 | $144.1K |
| Nov 3, 2025 | Hippel James CFO | Tax withheld | 11,865 | $742.4K |
| Nov 3, 2025 | Geist William PRESIDENT, PROTEIN SCIENCES | Option exercise | 9,911 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BIO-TECHNE Corp
Free account. Everything above stays public.
Write why you follow BIO-TECHNE Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading